Ausgewählte Studien

J Dtsch Dermatol Ges. 2023 Apr 26. doi: 10.1111/ddg.15071. Online ahead of print. ABSTRACT BACKGROUND: There is a growing understanding of inflammation in psoriasis beyond its dermatological manifestation, towards systemic inflammation. Management of possible comorbidities encompassing psychological, metabolic and cardiovascular disease is recommended in national and international dermatology guidelines for treatment of psoriasis patients. Vice versa, psoriasis is being recognized as a new risk

J Dtsch Dermatol Ges. 2023 May;21(5):537-539. doi: 10.1111/ddg.15013_g. NO ABSTRACT PMID:37183749 | DOI:10.1111/ddg.15013_g Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 May;21(5):473-481. doi: 10.1111/ddg.15007_g. ABSTRACT HINTERGRUND UND ZIELE: Die steigende Anwendung von Biologika bei der Behandlung entzündlicher Erkrankungen hat zu mehr Leishmaniose-Fällen bei Patienten mit iatrogener Immunsuppression geführt. Vorrangiges Ziel war die Beschreibung der Charakteristika von Patienten mit kutaner (CL) oder mukokutaner (MCL) Leishmaniose, die zum Zeitpunkt der Diagnose mit Biologika behandelt wurden. PATIENTEN UND METHODEN: Mit Kohorte

J Dtsch Dermatol Ges. 2023 May;21(5):445-454. doi: 10.1111/ddg.14991_g. ABSTRACT Psoriasis ist eine der häufigsten chronisch-entzündlichen Hauterkrankung, die mit systemischen Entzündungsreaktionen einhergeht und die Lebensqualität betroffener Patienten stark beeinträchtigt. In den letzten Jahren wurden mehrere hochwirksame Therapeutika für die Psoriasis zugelassen. In der Praxis kommt es jedoch bei einem hohen Anteil der Patienten nicht zu der in klinischen Studien beobachteten klinischen Verbe

J Dtsch Dermatol Ges. 2023 May;21(5):493-503. doi: 10.1111/ddg.14994_g. ABSTRACT HINTERGRUND UND ZIELE: Die Assoziation zwischen Psoriasis und Migräne zu beurteilen. PATIENTEN UND METHODIK: MEDLINE, Embase und Cochrane Central Register of Controlled Trials wurden vom Zeitpunkt ihrer jeweiligen Gründung bis zum 1. Mai 2022 nach relevanten Beobachtungsstudien durchsucht. Die Risikoeinschätzung zur Quantifizierung der Assoziationen zwischen Psoriasis und Migräne wurde anhand einer Metaanalyse mit Z

Actas Dermosifiliogr. 2023 May 10:S0001-7310(23)00346-0. doi: 10.1016/j.ad.2023.02.022. Online ahead of print. ABSTRACT The advent of biosimilar drugs and their use in routine clinical practice has revolutionized the management of moderate to severe psoriasis and led to changes in the positioning of the existing molecules used to control this condition. Evidence from clinical trials complemented by real-world experience has helped to clarify concepts and has significantly changed the use and pos

Monatsschr Kinderheilkd. 2023;171(5):420-429. doi: 10.1007/s00112-023-01764-0. Epub 2023 Apr 12. ABSTRACT Psoriasis is nowadays regarded as a multifactorial, inflammatory, immune-mediated systemic condition with predominant involvement of the skin. It starts in about one third of cases in childhood and adolescence and is often accompanied by marked impairment of the quality of life of sufferers and their parents. Aside from genetic disposition, trigger factors such as streptococcal infections ar

Biofactors. 2023 May 4. doi: 10.1002/biof.1949. Online ahead of print. ABSTRACT Psoriasis is an immune-mediated inflammatory skin disease driven by interleukin-17A (IL-17A) and associated with cardiovascular dysfunction. We used a severe psoriasis mouse model of keratinocyte IL-17A overexpression (K14-IL-17Aind/+ , IL-17Aind/+ control mice) to investigate the activity of neutrophils and a potential cellular interconnection between skin and vasculature. Levels of dermal reactive oxygen species (R

Real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. The objective was thus to examine real-world …Den ganzen Artikel lesen

Dear Editor In recent years, the association between low levels of vitamin D (measured as plasma 25-hydroxyvitamin D) and psoriasis has been debated. …Den ganzen Artikel lesen

Den ganzen Artikel lesen

SYSTEMATIC REVIEW The prevalence of anxiety disorders in dermatology outpatients: a systematic review and meta-analysis B. Storer The Black Dog …Den ganzen Artikel lesen

Acta Derm Venereol. 2023 Apr 21;103:adv5382. doi: 10.2340/actadv.v103.5382. ABSTRACT Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development. PMI

Background: Patients' understanding of the systemic nature of psoriatic disease (PsD) remains insufficiently explored. Objectives: To assess patients' …Den ganzen Artikel lesen

SummaryBackground and objectivesPsoriasis is a common skin disorder with a high physical and psychological burden for patients. Up to 30% of the …Den ganzen Artikel lesen

I-Hsin Huang, I-Hsin Huang Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Search for more papers by this author Wei-Kai …Den ganzen Artikel lesen

Joint Bone Spine. 2023 Apr 18:105579. doi: 10.1016/j.jbspin.2023.105579. Online ahead of print. ABSTRACT OBJECTIVE: To assess the value of referral strategies for axial spondyloarthritis (axSpA) in patients with suspicious chronic inflammatory low back pain (LBP), to estimate the value of inflammatory back pain (IBP) for referral, and to identify the predictive factors of the final diagnosis of axSpA in Middle Eastern Arab countries. METHODS: The study was multicentric, prospective, and conducte

J Dtsch Dermatol Ges. 2023 Apr 19. doi: 10.1111/ddg.15030. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: Psoriasis is a common skin disorder with a high physical and psychological burden for patients. Up to 30% of the patients are candidates for a systemic treatment. The aim of this study was to describe the characteristics and the real-world systemic treatment of psoriasis patients. PATIENTS AND METHODS: This study was based on German medical claims data. A cross-sectional analysis

I-Hsin Huang, I-Hsin Huang Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Search for more papers by this author Wei-Kai …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2023 Apr 15:S0001-7310(23)00292-2. doi: 10.1016/j.ad.2023.04.013. Online ahead of print. ABSTRACT Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease (MAFLD). Not only is MALFD diagnosed more often in patients with psoriasis, but its clinical course is also more aggressive. A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis. Especially impor

Research letter| Volume 88, ISSUE 5, P1129-1131, May 2023 Academic & Personal: 24 hour online access • Corporate R&D Professionals: 24 hour online …Den ganzen Artikel lesen

SummaryBackground and objectivesThe increasing use of biologics in the treatment of inflammatory diseases has led to more cases of leishmaniasis in …Den ganzen Artikel lesen

Ann Med. 2023 Dec;55(1):1335-1345. doi: 10.1080/07853890.2023.2192957. ABSTRACT BACKGROUND: Determining tumor necrosis factor-alpha inhibitors (anti-TNF-α) failure is still a challenge in the management of moderate-to-severe psoriasis. Thus, our comprehensive systematic literature review aimed to gather information on the criteria used to define anti-TNF-α failure. We also aimed to discover the main reasons for anti-TNF-α failure and define subsequently administered treatments. MATERIALS AND MET

Acta Derm Venereol. 2023 Apr 4;103:adv3962. doi: 10.2340/actadv.v103.3962. ABSTRACT The impact of dermatological diseases goes beyond symptoms and often includes psychosocial burden. Self-stigmatization plays a key role in this relationship and was compared in patients with psoriasis and atopic dermatitis to evaluate the validity of cross-disease stigmatization models. In total, 101 patients per indication were included in this cross-sectional study. Besides sociodemographic and clinical data, p

Front Immunol. 2023 Mar 16;14:1107438. doi: 10.3389/fimmu.2023.1107438. eCollection 2023. ABSTRACT BACKGROUND: The rate of seroconversion after COVID-19 vaccination in patients with moderate to severe psoriasis requiring systemic treatment is poorly understood. OBJECTIVES: The aim of this prospective single-center cohort study performed between May 2020 and October 2021 was to determine the rate of seroconversion after COVID-19 vaccination in patients under active systemic treatment for moderate